Sanofi SA (NASDAQ: SNY) announced on Monday that it has agreed to acquire Blueprint Medicines Corporation (NASDAQ: BPMC) in a deal valued at approximately $9.1 billion. This acquisition includes the rare immunology disease medicine Ayvakit\/Ayvakyt (avapritinib), which has been approved in both the U.S. and the EU, as well as an advanced and early-stage immunology pipeline.<\/p>\n\n\n\n
Ayvakit\/Ayvakyt is the only approved medicine for advanced and indolent systemic mastocytosis (ASM & ISM), a rare immunology disease. It targets the accumulation and activation of aberrant mast cells in several organs including bone marrow, skin, and the gastrointestinal tract. The acquisition also includes elenestinib, a next-generation medicine for systemic mastocytosis, and BLU-808, a potent oral inhibitor that holds promise for treating immunology diseases.<\/p>\n\n\n\n
Sanofi will pay $129.00 per share in cash, representing an equity value of around $9.1 billion. Blueprint shareholders will also receive a contingent value right (CVR), which entitles them to two potential milestone payments of $2 and $4 per CVR. These payments are contingent on the achievement of future development and regulatory milestones for BLU-808. With the CVR, the total equity value of the transaction could rise to approximately $9.5 billion on a fully diluted basis.<\/p>\n\n\n\n
Paul Hudson, CEO of Sanofi, highlighted that this acquisition is a strategic step forward for the company\u2019s rare and immunology portfolios. Sanofi has been focusing on acquiring early-stage medicines, and this deal complements their broader strategy. With Ayvakit\u2019s growth and Sanofi\u2019s continued capacity for acquisitions, the company is solidifying its position in the immunology field.<\/p>\n\n\n\n
Ayvakit achieved net revenues of $479 million in 2024, and the first quarter of 2025 saw nearly $150 million in revenues, representing a year-on-year growth of more than 60%. This strong performance further reinforces the value of the acquisition.<\/p>\n\n\n\n
Sanofi expects to complete the acquisition in the third quarter of 2025. The deal is not anticipated to significantly affect Sanofi’s financial guidance for 2025 but is expected to be accretive to gross margin, business operating income, and EPS after 2026.<\/p>\n\n\n\n
Additionally, Sanofi exercised its option to exclusively license Nurix Therapeutics, Inc.\u2019s (NASDAQ: NRIX) STAT6 program, including the drug candidate NX-3911. STAT6 plays a key role in type 2 inflammation associated with diseases like asthma and atopic dermatitis. As part of the agreement, Nurix will receive a $15 million license extension fee from Sanofi, bringing the total amount received to $127 million, with potential future royalties and milestones.<\/p>\n\n\n\n
As of the latest premarket session, Sanofi’s stock is trading lower by 0.73% at $49.01, Blueprint Medicines’ stock rose 26.8% to $128.50, and Nurix Therapeutics’ stock decreased by 0.28% to $10.60.<\/p>\n\n\n\n
<\/p>\n","protected":false},"excerpt":{"rendered":"
Sanofi SA (NASDAQ: SNY) announced on Monday that it has agreed to acquire Blueprint Medicines Corporation (NASDAQ: BPMC) in a deal valued at approximately $9.1 billion. This acquisition includes the rare immunology disease medicine Ayvakit\/Ayvakyt (avapritinib), which has been approved in both the U.S. and the EU, as well as an advanced and early-stage immunology<\/p>\n","protected":false},"author":5,"featured_media":6570,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[4007,4001,4006,4002,4011,699,4012,729,4003,4005,4010,4008,441,4004,4009,94],"class_list":{"0":"post-6569","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-business","8":"tag-9-1-billion-deal","9":"tag-ayvakit","10":"tag-blu-808","11":"tag-blueprint-medicines","12":"tag-contingent-value-right","13":"tag-drug-development","14":"tag-elenestinib","15":"tag-fda-approval","16":"tag-immunology","17":"tag-nurix-therapeutics","18":"tag-pharmaceutical-deal","19":"tag-rare-diseases","20":"tag-revenue-growth","21":"tag-sanofi-acquisition","22":"tag-stat6-program","23":"tag-stock-market"},"_links":{"self":[{"href":"https:\/\/guardianglobe.org\/index.php?rest_route=\/wp\/v2\/posts\/6569"}],"collection":[{"href":"https:\/\/guardianglobe.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/guardianglobe.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/guardianglobe.org\/index.php?rest_route=\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/guardianglobe.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=6569"}],"version-history":[{"count":1,"href":"https:\/\/guardianglobe.org\/index.php?rest_route=\/wp\/v2\/posts\/6569\/revisions"}],"predecessor-version":[{"id":6571,"href":"https:\/\/guardianglobe.org\/index.php?rest_route=\/wp\/v2\/posts\/6569\/revisions\/6571"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/guardianglobe.org\/index.php?rest_route=\/wp\/v2\/media\/6570"}],"wp:attachment":[{"href":"https:\/\/guardianglobe.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=6569"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/guardianglobe.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=6569"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/guardianglobe.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=6569"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}